Drug approved to treat high blood pressure

(HealthDay) -- The high blood pressure drug Toprol XL has been combined with a low-dose diuretic to form Dutoprol (metoprolol succinate extended release/hyrdrochlorothiazide), which has been approved by the U.S. Food and Drug Administration to treat high blood pressure.

Toprol XL has been approved in the United States for 20 years as a treatment for hypertension, British drugmaker AstraZeneca said in a news release.

The drug maker said it will charge $18.33 per month when a 90-day supply of the combination drug is ordered with a valid prescription, whether or not the patient has insurance. Retail drug stores also will stock the combination medication.

AstraZeneca said the drug may not be recommended for people with a significantly slow heart rate, uncontrolled heart failure, or allergies to the drug's ingredients.

More information: Medline Plus has more information about Dutoprol's active ingredient.

add to favorites email to friend print save as pdf

Related Stories

FDA approves a new beta blocker

Dec 18, 2007

The U.S. Food and Drug Administration has approved Bystolic, a beta blocker, for the treatment of high blood pressure. Bystolic (nebivolol) is a new drug not previously approved for use in the United States.

Two pancreatic-enzyme products approved

Mar 02, 2012

(HealthDay) -- Two drugs that supplement the digestion-aiding actions of pancreatic enzymes have been approved by the U.S. Food and Drug Administration, the agency said Thursday in a news release.

FDA approves skin cancer drug

Oct 13, 2006

The U.S. Food and Drug Administration approved a new drug to treat a rare, slow-growing skin cancer.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments